A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
Latest Information Update: 31 Jul 2021
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Alder Biopharmaceuticals
- 06 Jun 2021 Results of pooled analysis from 4 studies: (NCT01772524, NCT02275117, NCT02559895 (PROMISE-1), and NCT02974153 (PROMISE-2)) assessing the cardiovascular safety profile, CV risk in patients with migraine and mild to moderate CV risk factors, with few CV- related TEAEs and in few patients starting new or changing their dose of CV medication, presented at the 63rd Annual Scientific Meeting of the American Headache Society.
- 10 Sep 2017 Results of this trial and 2 other trials (refer CTP: 250744, 259778) were presented at the 2017 International Headache Society
- 15 May 2015 According to an Alder Biopharmaceuticals media release, data from this trial were presented at the 17th Congress of the International Headache Society.